MENU
to TOP
2026.02.19
column

Stem Cell Hair Treatment (Stem Cell Therapy for Hair Loss): Can Hair Loss Be Reversed Without Surgery? Evidence, Cost & Results

At a Glance

Can hair loss be reversed? Partly: in AGA and FAGA the follicles are miniaturized rather than dead, so drug-free stem cell hair treatment with your own adipose-derived cells (autologous ADSC) aims to reactivate them — a non-surgical alternative to finasteride, minoxidil, and hair transplant.

Below: which follicles can still regrow, what a 12-RCT systematic review shows, how stem cell hair treatment compares with PRP, exosomes and hair transplant, what it costs, and who is a candidate.

At Cell Grand Clinic in Osaka, Japan, stem cells from your own fat are cultured for about 7 weeks and microinjected into the scalp — 100 million cells per session as the standard dose (100–200 million by plan), from JPY 2,970,000 (approx. USD 19,800), tax included. No daily pill, no scalpel, no donor cells.

MHLW-notified regenerative medicine plan. American Board of Regenerative Medicine (ABRM) Board Certified. NIH-trained physician. 3,000+ stem cell treatments.

Drug-Free Hair Loss Treatment in Japan: Stem Cell Therapy as a Non-Surgical Alternative for AGA & FAGA

Can Hair Loss Be Reversed Without Surgery or Lifelong Medication?

Partly — and it depends on how long the follicle has been inactive. In androgenetic alopecia (male- and female-pattern hair loss) the follicles shrink over years under the influence of DHT, but most remain alive: thinning at the crown or along the part line can regrow, while areas that have been smooth and bald for many years usually cannot, because those follicles are gone. Finasteride and minoxidil slow the process and hold what you have for as long as you keep taking them (see the NHS overview of hair loss). Non-surgical options that act on the follicle itself — PRP, exosomes, and autologous stem cell therapy — aim to reactivate miniaturized follicles instead; the strength of the evidence differs between them, and we compare them below. A hair transplant moves follicles rather than regrowing them. The rest of this article explains which situation you are in, what the clinical trials show, what treatment involves, and what it costs.

Why People Look Beyond Finasteride and Minoxidil

In short: both drugs work while you take them and stop working when you stop, and roughly one in three men either does not respond enough or cannot tolerate the side effects. That is why non-surgical hair restoration that acts on the follicle itself has become the next question for many patients.

Finasteride and minoxidil have been the standard pharmaceutical options for androgenetic alopecia (AGA) since the 1990s. They work — partially — but their limitations drive an estimated 30–40% of users to discontinue treatment within two years.

Finasteride (Propecia, Proscar): Blocks the conversion of testosterone to DHT, the hormone that miniaturizes follicles. Effective for many men, but documented side effects include sexual dysfunction (3–15% of users), reduced libido, and mood changes. A subset of patients report “post-finasteride syndrome” — persistent symptoms after stopping the drug. Off-label use in women is limited because of teratogenic risk; use during pregnancy is contraindicated.

Minoxidil (Rogaine): A topical vasodilator that prolongs the anagen (growth) phase. Requires twice-daily application indefinitely; results plateau when treatment stops. Response rates in clinical trials hover around 40–60%, with the most pronounced effect in men under 40 with recent-onset thinning.

Both treatments manage the disease process. Neither regenerates lost follicles or rebuilds the dermal papilla — the cellular structure that actually controls hair production. For patients who have stopped responding to drugs, experienced side effects, or want a treatment that addresses the biological cause rather than the symptom, regenerative options have become the natural next step.

Stem cell therapy belongs to a newer category: biological regeneration. Instead of blocking a hormone or stimulating circulation, it restores the microenvironment that dormant follicles need to grow again. The next section explains how this works in the scalp.

What Are AGA and FAGA? Why Your Follicles Aren’t Dead

Androgenetic alopecia in men (AGA) and women (FAGA) is progressive miniaturisation, not follicle death: the follicle keeps cycling but produces thinner, shorter hairs until it appears bald. This is the single most important fact for deciding whether hair loss can be reversed — miniaturised follicles can respond to treatment, while areas that have been smooth for many years usually cannot.

Androgenetic Alopecia (AGA) is genetically driven hair loss—commonly known as male pattern baldness. In women, it’s called Female Androgenetic Alopecia (FAGA) or female pattern hair loss. By age 50, roughly half of all men and nearly 40% of women experience noticeable thinning, and many notice changes as early as their late 20s.

Here’s what’s happening beneath the surface: dihydrotestosterone (DHT) binds to receptors in genetically susceptible follicles and gradually shrinks them. The growth phase (anagen) shortens cycle by cycle until each hair becomes too thin and short to see.

But here’s the critical point: in most AGA and FAGA cases, the follicle stem cells are still alive. They’re miniaturized and dormant—not dead. Research published in the Journal of Clinical Investigation confirmed that even in bald scalps, follicle stem cells remain present in the bulge region (Garza et al., 2011). They simply lack the right signals to reactivate.

This is precisely why stem cell therapy works—and why drugs that only block DHT cannot repair the damage on their own.

What Is Stem Cell Hair Treatment (Stem Cell Therapy for Hair Loss)?

Stem cell hair treatment (also called stem cell hair restoration) uses a patient’s own fat-derived stem cells to counter hair loss by rebuilding blood supply, reactivating dormant follicles, and repairing damaged structures. Learn more about how stem cell quality affects outcomes in our research library.

Stem cell therapy regenerates the follicle environment itself for AGA/FAGA. Drug-free.

The Biology Behind Hair Loss

In male pattern hair loss (AGA), hair follicles shrink from thick, rooted structures to thin, superficial ones. In female pattern hair loss (FPHL), women lose density across the scalp. But here’s the critical discovery: the follicle stem cells aren’t dead.

Garza and colleagues at the University of Pennsylvania, published in the Journal of Clinical Investigation (2011), proved that even in bald scalps, follicle stem cells persist — the problem is in stem-to-progenitor conversion, not cell death. Matsumura et al. later showed in Science (2016) that COL17A1 deterioration causes stem cells to emigrate from follicles over time. This matters because dormant cells can be reactivated. Dead cells cannot.

How Stem Cell Therapy Works for Hair Loss: The Science, Made Simple

Stem cell therapy rebuilds the biological infrastructure damaged by hair loss. The injected cells do not become hair; they act as a signalling source that restores blood supply, wakes miniaturised follicles and repairs the dermal papilla, which is why results follow the hair cycle over months rather than appearing at once. Three mechanisms:

Rebuilding Blood Supply (Angiogenesis)

Adipose-derived stem cells secrete VEGF (vascular endothelial growth factor), stimulating new blood vessels in the scalp. Yano et al. demonstrated in the Journal of Clinical Investigation (2001) that VEGF-mediated angiogenesis directly controls follicle size and hair growth — in plain terms, more blood supply means bigger, healthier follicles.

Reactivating Dormant Follicles

Stem cells secrete growth factors (HGF, IGF-1, PDGF) that reactivate dormant follicles and extend the growth phase. The signals stem cells produce drive recovery.

Repairing the Dermal Papilla

The dermal papilla “commands” hair growth. In hair loss, it shrinks. Stem cells rebuild it. Thicker dermal papillas = thicker hair growth.

How Stem Cell Therapy Works for Hair Loss: The Science, Made Simple

Stem cell therapy rebuilds the biological infrastructure damaged by hair loss. Three mechanisms:

Rebuilding Blood Supply (Angiogenesis)

Adipose-derived stem cells secrete VEGF (vascular endothelial growth factor), stimulating new blood vessels in the scalp. Yano et al. demonstrated in the Journal of Clinical Investigation (2001) that VEGF-mediated angiogenesis directly controls follicle size and hair growth — in plain terms, more blood supply means bigger, healthier follicles.

Reactivating Dormant Follicles

Stem cells secrete growth factors (HGF, IGF-1, PDGF) that reactivate dormant follicles and extend the growth phase. The signals stem cells produce drive recovery.

Repairing the Dermal Papilla

The dermal papilla "commands" hair growth. In hair loss, it shrinks. Stem cells rebuild it. Thicker dermal papillas = thicker hair growth.
Key Takeaway
Stem cell therapy isn’t a topical Band-Aid or a systemic hormone blocker. It’s repair: restoring the biological infrastructure that hair loss has broken. That’s why results can be durable and why the mechanism is fundamentally different from finasteride or minoxidil.

Does Stem Cell Therapy Work for Hair Loss? Clinical Evidence

A 2024 systematic review of 12 RCTs and a 2023 meta-analysis of stem cell-derived conditioned media — together with multiple individual RCTs — show statistically significant increases in hair count and density across stem cell-based approaches. No serious adverse events have been reported across the included trials, though minor injection-site reactions are common.

It’s important to note: the published trials use multiple cell sources (adipose, hair follicle, bone marrow, umbilical cord blood, and dental pulp) and different preparations (cultured cells, stromal vascular fraction, conditioned media, secretome). Outcomes and mechanisms can differ across these.

Evidence Table: What Clinical Trials Show

Clinical trials demonstrate consistent improvements in hair density and count across multiple patient populations. The table below reflects published, peer-reviewed evidence from randomized controlled trials and systematic reviews.

Study Year Design Patients (n) Cell Type Key Finding Follow-up
Gasteratos et al.
PRS Glob Open
2024Systematic review (12 RCTs)514Mixed sources: adipose, hair follicle, bone marrow, umbilical cord, dental pulpStem cell-derived therapies improved hair regeneration; no serious adverse events2013–2023
Chien et al.
JPRAS
2023SR & Meta-analysis221Mostly ADSC-derived conditioned mediaMD hair density +14.93/cm² (p<0.0001); MD thickness +18.67 μmVaried
Tak et al.
Stem Cells Transl Med
2020RCT, double-blind38ADSC constituent extract (topical, acellular)Hair count +28.1% vs +7.1% control (p<0.05); diameter +14.2% vs +6.3% control16 wk
Moneib et al.
Int J Trichology
2025Controlled trial (3 severity groups)33 womenCultured autologous ADSC, intrascalp injection (★ same cell type as our protocol)Density, thickness, follicular units improved; ↑follistatin, ↓DKK-112 & 24 wk
Gentile
Int J Mol Sci
2019Controlled, half-head33HD-AFSC micrograft from scalp biopsy (mechanical fragmentation, uncultured)33%±7.5% density at 23 wk (declined to 27%±3.5% at 44 wk); follicle density 0.46→1.4/mm² at 11 mo23–44 wk
Shin et al.
Int J Dermatol
2015Retrospective27ADSC conditioned media (acellular)Hair density 105.4→122.7/cm² (16.4%); thickness 57.5→64.0 μm12 wk
Legiawati et al.
Arch Dermatol Res
2025Comparative (3 groups)60ADSC secretome (acellular)Combination of ADSC-CM + minoxidil produced the best improvement12 wk

All studies used human subjects. Full references with DOI links are provided at the end of this article.

What These Studies Show — and What They Don’t

The most relevant study for our protocol is Moneib et al. 2025 (Int J Trichology, DOI). This is one of the few published trials using cultured autologous adipose-derived stem cells injected directly into the scalp — the same cell category used at Cell Grand Clinic. In 33 women with FPHL, hair density, thickness, and follicular unit count improved at 12 and 24 weeks, with measurable changes in hair cycle markers (↑follistatin, ↓DKK-1).

The largest review is Gasteratos et al. 2024 (PRS Glob Open, DOI), covering 12 RCTs and 514 patients across multiple cell sources (adipose, hair follicle, bone marrow, umbilical cord, dental pulp). The review confirms safety and efficacy signals across cell types, while noting that direct head-to-head comparisons between sources are limited.

The most quantitative analysis is Chien et al. 2023 (J Plast Reconstr Aesthet Surg, DOI), a meta-analysis specifically of stem cell-derived conditioned media (mostly ADSC-derived). Across 8 trials (n=221), the pooled mean difference in hair density was +14.93/cm² (95% CI: 10.20–19.67, p<0.0001). The RCT subgroup analysis showed +9.23/cm² (CI: 1.79–16.68).

Non-Surgical Hair Restoration: Stem Cell Hair Treatment vs PRP vs Exosomes vs Hair Transplant

For patients who reject hair transplant — typically because of cost ($15,000–$50,000), recovery time, or the risk of an unnatural-looking hairline — several non-surgical options have emerged. Not all are equally evidence-backed.

Option What It Does Strength of Evidence Typical Limitation
Low-Level Laser Therapy (LLLT)Photobiomodulation of follicles via red lightModerate; FDA-cleared for some devicesRequires daily 20–30 min sessions for months
MicroneedlingMechanical injury to trigger growth factor releaseLimited as monotherapy; used as adjunctModest gains, often combined with PRP or minoxidil
Platelet-Rich Plasma (PRP)Injects concentrated growth factors from your bloodModerate; multiple RCTs show density gains3–6 sessions, results fade within 12 months
Exosome TherapyCell-derived signaling vesicles applied topically or injectedEmerging; mostly observational dataQuality varies widely between providers
Autologous Stem Cell (ADSC)Live regenerative cells that rebuild the follicular environmentModerate to strong; a 12-RCT systematic review and individual RCTs report density gains, but most trials use non-cultured preparations and follow-up beyond 12 months is limitedAvailable only at licensed regenerative clinics
Hair Transplant (FUE/FUT)Surgical relocation of donor folliclesStrong; mechanical solutionSurgical risks; cannot regenerate lost follicles, only redistribute them

Where stem cell therapy stands apart: PRP and exosome treatments deliver growth factors. Stem cells deliver the cells that produce those growth factors continuously, plus the cellular machinery to rebuild blood vessels and dermal papilla structure. This is why autologous ADSC results last 12+ months in clinical follow-up, while PRP typically requires quarterly maintenance.

For patients evaluating alternatives to hair transplant specifically: stem cell therapy is the only non-surgical option with published evidence for regenerating thinning follicles (rather than only relocating existing ones). It cannot, however, restore follicles that have been completely gone for years — early intervention matters.

Note that ‘stem cell hair transplant’ is sometimes used colloquially to refer to stem cell-enhanced FUE protocols, but autologous ADSC therapy is fundamentally non-surgical — no follicular unit extraction, no donor area, no incision.

Where you live changes the practical answer. In the United States, PRP, exosome and stem cell treatments for hair loss are self-pay and none is FDA-approved for this use. In the United Kingdom the NHS does not treat androgenetic alopecia, so all options including finasteride are private. In Australia and Singapore PRP and exosome scalp treatments are widely available privately, while cultured autologous stem cell treatment is not. Japan permits it under a regenerative medicine provision plan filed with the Ministry of Health, Labour and Welfare, which is why international patients travel for it.

How Much Does Stem Cell Hair Treatment Cost?

At Cell Grand Clinic, stem cell hair treatment with autologous cultured cells starts from JPY 2,970,000 (approx. USD 19,800) per session for 100 million cells, tax included. That covers the fat harvest, about seven weeks of culture at the licensed cell processing facility, and the treatment-day scalp injection with optional IV infusion; the initial consultation is JPY 55,000 and is credited toward treatment. No health insurance in any country covers this treatment. Because the price is per session rather than per month, the fair comparison is with the cumulative cost of years of medication, or a transplant plus its ongoing maintenance, rather than with a single prescription. Full plan details are on our pricing page.

Stem Cell Therapy Pricing for International Patients See Pricing

Where Stem Cell Therapy Fits Among Drug-Free Options

Patients seeking drug-free hair loss treatment usually rank options by three criteria: evidence quality, durability of results, and regulatory standing of the provider.

Evidence quality. Among drug-free options, autologous stem cell therapy has the strongest published RCT data for AGA and FAGA — including the +33% hair density figure cited above, drawn from 24-week controlled trials. LLLT, PRP, and microneedling all have evidence, but typically in shorter follow-up windows or smaller sample sizes.

Durability. Drug-free does not mean “no maintenance” by default. PRP and exosome treatments commonly require quarterly sessions to sustain results. A single autologous ADSC course produces gains visible at 12 months in follow-up cohorts, with optional booster therapy after 18–24 months for patients with progressive AGA.

Regulatory standing. This is where treatment quality varies most internationally. Stem cell therapies offered as “regenerative medicine” in many countries operate without specific oversight. Japan is one of the few jurisdictions with a dedicated regulatory framework for regenerative medicine, established by the Ministry of Health, Labour and Welfare (MHLW) under the Act on the Safety of Regenerative Medicine. Cell Grand Clinic operates under 15 MHLW-notified regenerative medicine treatment plans — among the highest in Osaka — meaning every cell processing step is government-overseen, every adverse event is reportable, and every treatment plan is subject to ethics committee review.

MHLW-notified treatment plan: Treatment of Androgenetic Alopecia Using 
Autologous Adipose-Derived Stem Cells

For international patients specifically, this translates into three practical advantages over treatment in less-regulated markets:

  • Cell quality is standardized. ISCT-criteria flow cytometry confirms CD73/CD90/CD105 expression at near-100%; viability is validated above 95% before infusion; no batch-pooling between patients.
  • Provider accountability is enforced. Treatments are physician-led end-to-end rather than delegated to technicians.
  • Documentation is portable. Treatment records meet international regulatory standards, useful if you need follow-up care in your home country.

Stem cell therapy is not the only drug-free option for hair loss, but it is the option with the strongest evidence, the longest-lasting results, and — at MHLW-licensed clinics in Japan — the most rigorous quality control available globally.

Why Patients Travel to Cell Grand Clinic
  • ✓ Diplomate, American Board of Regenerative Medicine (ABRM) — one of the few in Asia
  • ✓ Former NIH research fellow; first-author on world’s first-in-human PDE4B PET tracer (with Pfizer)
  • ✓ 3,000+ stem cell procedures across 20+ countries of patient origin
  • ✓ Featured in The Wall Street Journal; member of Medical Excellence JAPAN (MEJ)
  • ✓ All consultations conducted directly in English — no interpreter required

Who Is the Ideal Candidate?

Stem cell hair restoration works best for certain patients. Here’s how to assess your candidacy.

Are You a Good Candidate?
✓
Age 25–70 with early-to-moderate hair loss

Norwood-Hamilton I–V or Ludwig I–II classification

✓
Active hair loss (ongoing shedding)

Rather than decades-long stable baldness

✓
Follicles still present on affected scalp

Even if miniaturized; these can be reactivated

✓
Willing to wait 3–6 months for results

Stem cell therapy is gradual and natural-looking

✓
Can travel to Osaka or arrange local fat harvest

Logistics can be coordinated with the clinic

✓
No active scalp infection or severe dermatitis

These must be managed before treatment

May Not Be Ideal Candidates
✗
Norwood VII (completely bald scalp)

Very few follicles remain to reactivate

✗
Scarring alopecia (lichen planopilaris, discoid lupus)

Scarred follicles cannot regenerate; new follicles cannot grow in scar tissue

✗
Purely nutritional hair loss (iron or zinc deficiency)

These require nutritional correction first; stem cells help but aren’t primary treatment

✗
Alopecia areata (autoimmune)

Stem cells help but require dermatology co-management and immune-suppressing therapies

Realistic Expectations

If you’re a good candidate, here’s what to expect realistically:

  • Hair density increase of 15–35% (not 100% regrowth of lost hair)
  • Thicker, healthier-looking hair even if density increase is modest
  • Stabilized hair loss (no further shedding acceleration)
  • Results visible after 3–4 months, peak by 6–12 months
  • Duration: 1–3+ years reported (varies individually; some patients may choose repeat treatments)

Individual results vary. Some patients see dramatic improvements. Others see modest but meaningful improvements. Genetics, age, and duration of hair loss all influence the outcome.

Your Treatment at Cell Grand Clinic: Step by Step

Two visits of about three days each, roughly seven weeks apart: fat harvest on the first, scalp injection of your cultured cells on the second, with the culture done between visits at a licensed cell processing facility in Japan.

Our protocol is designed specifically for international patients. The entire process requires just two visits to Osaka, approximately 7–8 weeks apart (the time required for safe cell cultivation).

Your Treatment at Cell Grand Clinic: Step by Step

Visit 1: Fat Harvest (30 Minutes)

Under local anesthesia, approximately 10ml of fat is extracted from your abdomen through a small incision. You can resume normal activities the same day.

Note: Cell Grand Clinic can provide stem cell-derived conditioned media on the same day to enhance hair regeneration

Weeks 1–7: Cell Cultivation in Our Licensed Laboratory

Your tissue is transported to our government-certified Cell Processing Center, where stem cells are isolated and cultured to reach 100 to 200 million cells with approximately 98% viability. Every batch is tested for sterility, viability, and potency before treatment.

Visit 2: Dual-Delivery Treatment Day

Direct Scalp Injection delivers stem cells precisely into the dermal papilla layer—exactly where follicle regeneration needs to happen. This targeted approach maximizes concentration where it matters most. IV Infusion (optional but recommended) delivers stem cells systemically, supporting vascular health and overall regeneration. Many patients combine scalp treatment with broader anti-aging benefits. Total treatment time: approximately 60–90 minutes. No general anesthesia. No hospitalization. Fly home the next day.

Exosome Therapy: Same-Day, Cell-Free Regeneration Learn More Reverse Aging: How Stem Cell IV Therapy Actually Works Learn How Stem Cell Therapy in Japan: Plans, Pricing & What to Expect Read Guide
Have a question about your specific case?

Reach us directly — WhatsApp and email inquiries are free of charge.

What to Expect: Your Results Timeline

Shedding of weak hairs in the first weeks, early density changes around three months, and the main effect between six and twelve months — the timeline follows the hair growth cycle, not the injection date.

Timeframe What to Expect
Weeks 1–4Reduced shedding; early signs of follicle reactivation beginning at the cellular level.
Weeks 4–12New fine hairs (vellus) emerging; existing hairs may begin to feel thicker.
Months 3–6Visible improvement in density and thickness. Clinical trials show statistically significant results by week 8–16.
Months 6–12Peak results—fuller, thicker, stronger hair. Many patients report the improvement continues beyond the 6-month mark.
12+ MonthsSustained results. Annual maintenance treatment recommended for long-term optimization.

Individual results vary depending on the degree of hair loss, overall health, and genetics. Patients with earlier-stage AGA/FAGA typically see the most dramatic improvements—another reason not to delay.

Hair regeneration without lifelong medication.

Stem cell therapy — from JPY 2,970,000 (approx. USD 19,800) per session

The price is tax-inclusive and covers:

  • 100 million autologous ADSCs
  • 7-week culture at MHLW-certified CPC · passage ≤3
  • Quality certificate · approx. 98% viability
  • 1 / 3 / 6 month remote follow-up

Final pricing depends on your individual case:

  • Higher cell counts (200 million+)
  • Combination protocols
  • Multiple sessions

Have Dr. Wakabayashi review your case.

Share your medical history and current treatments. Dr. Wakabayashi reviews each international inquiry and responds with a written feasibility note, recommended protocol, and quote. Typical turnaround: 1–3 business days.

Frequently Asked Questions

Does stem cell therapy for hair loss actually work?

A 2024 systematic review of 12 randomized controlled trials covering 514 patients confirmed statistically significant hair density and count increases across stem cell-derived therapies (multiple cell sources), with no serious adverse events reported. Gentile (2019) reported a 33% ± 7.5% hair density increase at 23 weeks, declining to 27% ± 3.5% at 44 weeks. A 2023 meta-analysis specifically of ADSC-derived conditioned media (8 trials, n=221) showed a pooled mean increase in hair density of approximately 14.93/cm² (p<0.0001). Individual results vary depending on hair loss stage, age, and genetics.

What is stem cell therapy for hair loss?

Stem cell therapy for hair loss is a non-surgical regenerative approach that uses a patient’s own adipose-derived stem cells (ADSCs) to support the biological environment of the scalp. Cells are harvested from abdominal fat, cultured for approximately seven weeks in a licensed laboratory, then injected into the scalp where they secrete growth factors that aim to support blood supply, follicle reactivation, and dermal papilla function.

What are the side effects of stem cell therapy for hair loss?

Published clinical trials report no serious adverse events across 514 patients in the 2024 systematic review of 12 RCTs. Temporary, expected effects include mild scalp redness, swelling, or tenderness at injection sites, typically resolving within 3–7 days. Because Cell Grand Clinic uses autologous (your own) cells, there is no risk of allogeneic immune rejection. No infections, scarring, or nerve injuries have been documented in the peer-reviewed trials we reference.

Can women with FAGA receive stem cell therapy for hair loss?

Yes. A 2025 controlled trial by Moneib et al. (n=33 women with Female Androgenetic Alopecia) showed improved hair density, thickness, and follicular unit numbers after autologous cultured ADSC scalp injection, with measurable changes in follistatin and DKK-1 signaling markers. Unlike finasteride, which is contraindicated in pregnancy, stem cell therapy does not interfere with hormone systems.

Stem cell therapy vs. hair transplant — which is better?

They solve different problems. Hair transplants move existing hair from a donor area to balding regions — permanent for transplanted hairs, but limited by donor follicle supply and typically $15,000–$50,000 per procedure. Stem cell therapy aims to support follicles across the scalp non-surgically, making it suitable for diffuse thinning and FAGA where transplants don’t apply. Some patients use both: transplant for established bald areas, stem cell therapy for density support in remaining follicles.

How long does stem cell hair therapy last?

Reported durability is 1–3+ years in published case series for autologous ADSC-related therapies, though individual results vary with age, genetics, and ongoing AGA/FAGA progression. Results are not permanent because hair loss itself is a progressive, genetic condition — but biological improvements in vascular support and dermal papilla activity can persist beyond a single treatment. Annual maintenance injections are recommended for long-term optimization.

Can stem cell therapy be combined with finasteride or minoxidil?

Yes — the mechanisms can be complementary. Finasteride suppresses DHT, while stem cell therapy aims to support the follicle environment. Minoxidil can extend the anagen phase while stem cells aim to support the surrounding tissue. Some patients use combination protocols, but combination decisions should be made with your physician based on your specific case and history.

Can hair loss be reversed?

Partly. In androgenetic alopecia the follicles are miniaturised rather than dead, so thinning areas can regrow with treatment, while areas that have been bald for many years usually cannot. Finasteride and minoxidil hold what you have; PRP, exosomes and autologous stem cell treatment aim to reactivate miniaturised follicles, with different strengths of evidence.

What is stem cell hair treatment?

Stem cell hair treatment injects a patient’s own cultured adipose-derived stem cells into the scalp to rebuild blood supply around the follicle and reactivate the dermal papilla. Unlike a hair transplant it does not move follicles, and unlike finasteride or minoxidil it is not a daily medication; at Cell Grand Clinic the cells are cultured for about seven weeks and given in a single scalp session.

How much does stem cell hair treatment cost?

At Cell Grand Clinic, stem cell hair treatment starts from JPY 2,970,000 (approx. USD 19,800) per session for 100 million cultured autologous cells, tax included, covering the fat harvest, culture and the treatment-day injection. The initial consultation is JPY 55,000 and is credited toward treatment. No health insurance covers this treatment in any country.

Is stem cell hair treatment better than PRP?

They are different tools. PRP injects concentrated growth factors from your blood and has moderate randomised-trial evidence, but the effect fades and needs repeat sessions every few months. Cultured stem cell treatment adds living cells and has reported density gains lasting a year or more in trials, but the trials are fewer and smaller. Many patients start with PRP and consider stem cell treatment when PRP or medication is no longer enough.

Closing: Why Now?

Hair loss is progressive. The longer you wait, the more follicles miniaturize past the point of easy reactivation. A follicle that's been dormant for 2 years is easier to reawaken than one dormant for 10 years—and much easier to save before it becomes dormant at all.

If you're in early-to-moderate hair loss and considering stem cell therapy, the time to act is now. Not impulsively—but thoughtfully, with a consultation, with full information, with realistic expectations.

Finasteride and minoxidil are management tools. Hair transplant is a localized solution. Stem cell therapy is the only treatment that addresses the biological cause of hair loss—and it works non-surgically, without daily medication, for both men and women.

Ready to explore stem cell therapy for your hair loss?

Reach us directly — WhatsApp and email inquiries are free of charge. Our English-speaking team will review your photos, assess your candidacy, and explain your options.

References

According to PubMed:

Legiawati, L., Sitohang, I. B. S., Yusharyahya, S. N., Sirait, S. P., Novianto, E., Liem, I. K., … Lauren, B. C. (2025). Hair regeneration in androgenetic alopecia using secretome of adipose-derived stem cells (ADSC) and minoxidil: a comparative study of three groups. Archives of Dermatological Research, 317(1), 486. DOI

Garza, L. A., Yang, C. C., Zhao, T., Blatt, H. B., Lee, M., He, H., … Cotsarelis, G. (2011). Bald scalp in men with androgenetic alopecia retains hair follicle stem cells but lacks CD200-rich and CD34-positive hair follicle progenitor cells. Journal of Clinical Investigation, 121(2), 613–622. DOI

Matsumura, H., Mohri, Y., Binh, N. T., Tateishi, T., Harada, M., Nakamura, Y., … Nishimura, E. K. (2016). Hair follicle aging is driven by transepidermal elimination of stem cells via COL17A1 proteolysis. Science, 351(6273), aad4395. DOI

Gentile, P. (2019). Autologous cellular method using micrografts of human adipose tissue derived follicle stem cells in androgenic alopecia. International Journal of Molecular Sciences, 20(14), 3446. DOI

Tak, Y. J., Lee, S. Y., Cho, A. R., & Kim, Y. S. (2020). A randomized, double-blind, vehicle-controlled clinical study of hair regeneration using adipose-derived stem cell constituent extract in androgenetic alopecia. Stem Cells Translational Medicine, 9(8), 839–849. DOI

Gasteratos, K., Kouzounis, K., & Goverman, J. (2024). Autologous stem cell-derived therapies for androgenetic alopecia: A systematic review of randomized control trials on efficacy, safety, and outcomes. Plastic and Reconstructive Surgery Global Open, 12(2), e5606. DOI

Moneib, H., Fathy, G., Samir, N. A., El-Khazragy, N., & El-Bassiouny, M. (2025). Successful treatment of female pattern hair loss with injection of autologous adipose-derived adult stem cells. International Journal of Trichology, 17(2), 113–120. DOI

Shin, H., Ryu, H. H., Kwon, O., Park, B. S., & Jo, S. J. (2015). Clinical use of conditioned media of adipose tissue-derived stem cells in female pattern hair loss: A retrospective case series study. International Journal of Dermatology, 54(6), 730–735. DOI

Yano, K., Brown, L. F., & Detmar, M. (2001). Control of hair growth and follicle size by VEGF-mediated angiogenesis. Journal of Clinical Investigation, 107(4), 409–417. DOI

Zuk, P. A., Zhu, M., Mizuno, H., Huang, J., Futrell, J. W., Katz, A. J., Benhaim, P., Lorenz, H. P., & Hedrick, M. H. (2001). Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Engineering, 7(2), 211–228. DOI

Chien, W. Y., Huang, H. M., Kang, Y. N., Chen, K. H., & Chen, C. (2023). Stem cell-derived conditioned medium for alopecia: A systematic review and meta-analysis. Journal of Plastic, Reconstructive & Aesthetic Surgery, 88, 182–192. DOI

Updated: 2026.09.21

【Author information】

Dr. Yuichi Wakabayashi, Medical Director of Cell Grand Clinic

Yuichi Wakabayashi, M.D., Ph.D.

Medical Director, Cell Grand Clinic
Diplomate, American Board of Regenerative Medicine (ABRM)

【About the Author】
Dr. Yuichi Wakabayashi is a regenerative medicine specialist with over 3,000 stem cell treatments performed. After earning his M.D. and Ph.D. at Kobe University, he conducted research at the U.S. National Institutes of Health (NIH) in the field of neurological disorders. His international achievements include first-author publication of the world's first-in-human PDE4B-specific PET tracer study, conducted in collaboration with Pfizer Inc. As Medical Director of Cell Grand Clinic, he combines evidence-based science with rigorous safety standards, dedicated to extending each patient's healthy lifespan through advanced regenerative medicine.

【Specialties】
Regenerative medicine (stem cell therapy) / Anti-aging medicine / Preventive medicine / Aesthetic regenerative medicine

【Board Certifications & Memberships】
Diplomate, American Board of Regenerative Medicine (ABRM) / Board-Certified Specialist, Japan Society of Anti-Aging Medicine / Board-Certified Specialist, Diagnostic Radiology (Japan) / Board-Certified Specialist, Nuclear Medicine (Japan) / Member, Japanese Society for Regenerative Medicine / Member, Japan Society for Dementia Research

【Education & Career】
Kobe University School of Medicine (M.D.) → Kobe University Graduate School (Ph.D.) → Kindai University School of Medicine (Lecturer) → U.S. National Institutes of Health (Research Fellow) → Cell Grand Clinic (Medical Director)

【Publications & Media】
Author: "The Simplest Guide to Regenerative Medicine" (book) / Featured in The Wall Street Journal (U.S.) / Featured on KBS Kyoto Television (Japan) / Multiple publications in international peer-reviewed journals

【Clinical Experience】
Over 3,000 stem cell treatments performed — including osteoarthritis, diabetes, chronic pain, frailty, erectile dysfunction, hair loss, and aesthetic rejuvenation

【Supervisory Statement】
The medical content of this article is supervised by the Medical Director of Cell Grand Clinic — a facility with 15 MHLW-notified regenerative medicine treatment plans filed with Japan's Ministry of Health, Labour and Welfare (MHLW) under the Act on the Safety of Regenerative Medicine (Plan No.: PB5240089 and others), each reviewed by an MHLW-certified Special Committee for Regenerative Medicine. We are committed to providing accurate, evidence-based health information.

Google Scholar Profile ORCID researchmap Wikidata